Perplexity AI Predicts Whether Moderna Stock Can Make Investors Rich in 2026
Perplexity AI forecasts Moderna stock at $180 to $240 by the end of 2026, with a $210 bullish base case. The prediction centers on Intismeran, a personalized mRNA cancer vaccine that Perplexity identifies as the dominant valuation driver. A single trial readout reportedly doubled a company's market value in one session, and Perplexity expects the rerating to continue.
DeFi Intel is an entity-graph aggregator: we curate, tag and link crypto news to a typed knowledge graph of protocols, tokens, people and incidents. We do not republish the full article body. Use the link above to read the original report at Cryptonews.
Entities in this story
Discussion
Comments are reviewed before publication.
Want the full article?
Continue reading on Cryptonews →
No comments yet.